Watine J, Charet J C, Bruel A, Bouilloux J P, Palliez J
Laboratory of Clinical Biology, Centre Hospitalier Général, Rodez, France.
Pathol Biol (Paris). 1996 Feb;44(2):125-31.
Over a four-year period, the systematic O-serotyping of all Pseudomonas aeruginosa isolated in Hôpital de Rodez associated with the use of a computerized expert system, facilitated the early detection of two outbreaks of nosocomial infections with multiresistant serotype O:11 and multiresistant serotype O:12 P. aeruginosa respectively involving ten patients over 16 months and six patients over six months. Over this four-year period, serotype O:12 represented 14% of 404 clinical isolates of P. aeruginosa, and most isolates of this serotype were resistant to multiple antibiotics. Combination experiments showed that fosfomycin/amikacin together were active against 86% of O:12 isolates. Fosfomycin/amikacin might be considered as a therapeutic alternative to ceftazime/amikacin for the presumptive antipseudomonal therapy of serotype O:12 infections.
在四年时间里，罗德兹医院对所有分离出的铜绿假单胞菌进行系统的O血清型分型，并使用计算机专家系统，这有助于早期发现两起医院感染暴发，分别是多重耐药血清型O:11和多重耐药血清型O:12的铜绿假单胞菌感染，在16个月内涉及10名患者，在6个月内涉及6名患者。在这四年期间，血清型O:12占404株铜绿假单胞菌临床分离株的14%，该血清型的大多数分离株对多种抗生素耐药。联合实验表明，磷霉素/阿米卡星联合使用对86%的O:12分离株有活性。对于血清型O:12感染的推定抗假单胞菌治疗，磷霉素/阿米卡星可被视为头孢他啶/阿米卡星的治疗替代方案。
